

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Aiping H. Young et al	Confirmation No.:	4680
Serial No.:	10/585,772	Art Unit:	1635
Filed:	November 13, 2007	Examiner:	Dana H. Shin
Customer No.:	21559		
Title:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF YOON LEE UNDER 37 C.F.R. § 1.131

I declare:

1. I am an inventor of the subject matter described and claimed in the above-captioned patent application.
2. Yoon Lee, Aikaterini Vassilakos, Ningping Feng, Viengthong Lam, Hongsheng Xie, Ming Wang, Hongnan Jin, Keyong Xiong, Chenyi Liu, Jim Wright, and Aiping Young (Cancer Res 2003 63: 2802-2811) was published in June 2003, not more than one year before the January 12, 2004 filing date of Applicants' priority application, U.S. Serial No. 60/535,496, which supports the present claims.
3. The experiments described in Lee et al. that relate to the invention were the joint contributions of the instant inventors, notwithstanding the inclusion of additional authors on the publication. The other named authors, Aikaterini Vassilakos, Ningping Feng, Viengthong Lam, Hongsheng Xie, Ming Wang, Hongnan Jin, Keyong Xiong, and Chenyi Liu, provided technical support and did not contribute to the claimed inventive matter.

4. All statements of my knowledge made herein are true and all statements made based upon information and belief are believed to be true; and, further, these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: August 31/09



Yoon Lee